Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute

Journal of Infection and Chemotherapy

Volumn 7, Issue 3, 2001, Pages 156-162

  Seo, T ^a   Fukushima, T ^a   Inoue, H ^a   Imamura, S ^a   Urasaki, Y ^a   Yoshida, A ^a   Kawai, Y ^a   Yamauchi, T ^a   Iwasaki, H ^a   Tsutani, H ^a   Nakamura, T ^a   Ueda, T ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Acute myeloid leukemia; Chemotherapy; Prognostic factor; Retrospective study; Survival

Indexed keywords

ACLARUBICIN; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; MITOXANTRONE; PREDNISOLONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; JAPAN; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 17944366043     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560100028     Document Type: Article

References (24)

1. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult myeloid leukemia
2. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia
3. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: The JALSG-AML 92 study
4. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
5. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
6. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes
7. 4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia
8. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells
9. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine
10. Acute myeloid leukemia in adult (except M3)
11. Acute myelogenous leukemia in the elderly: Retrospective study of 235 consecutive patients
12. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
13. Principal results of the Medical Research Council's Eighth Acute Myeloid Leukemia Trial
14. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia
15. Effect of age on survival in acute leukemia
16. Randomized multicenter trial comparing daunorubicin with mitoxantrone in combination with non-cross-resistant multidrugs in adult patients with newly diagnosed acute non-lymphocytic leukemia
17. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
18. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study
19. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
20. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
21. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
22. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenic subtype
23. Clinical pharmacology of intermediate-dose ara-C therapy in patients with acute leukemia
24. Chemotherapy of acute leukemia